Association of oral manifestations with severity of the disease in ulcerative colitis patients.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
24 Oct 2024
Historique:
received: 12 06 2024
accepted: 21 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions primarily affecting the intestines. This study aims to identify the nature and frequency of oral symptoms and signs in patients with ulcerative colitis and to explore the connection between these complications and the activity of the disease. This descriptive-analytical study involved ulcerative colitis patients who visited the gastroenterology clinic at Shahid Sayad Shirazi Hospital in Gorgan, along with an equal number of healthy companions as a control group in 2019. A gastroenterology internist assessed the disease severity through clinical examination and a simple clinical disease activity index for colitis patients. The collected data were then analyzed statistically using SPSS version 19. The average age of patients in the case group was 41.84 ± 11.66 years, while in the control group it was 40.43 ± 12.67 years. There was a significant correlation between difficulty swallowing, burning sensation in the mouth, vomiting, acidic taste, the presence of oral ulcers, and a coated tongue with the severity of disease activity (p < 0.05). However, no significant relationship was found between other variables and the severity of disease activity (p > 0.05). The results of this study confirm that as the severity of ulcerative colitis increases, the occurrence of oral lesions also rises, particularly during severe disease activity. Among oral symptoms, dry mouth had the highest incidence, followed by bad breath and changes in taste. The most common oral lesions observed were a coated tongue, grooved tongue, and oral ulcers, respectively.

Identifiants

pubmed: 39448908
doi: 10.1186/s12876-024-03472-9
pii: 10.1186/s12876-024-03472-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

378

Informations de copyright

© 2024. The Author(s).

Références

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. PMID: 27914657; PMCID: PMC6487890.
Caioni G, Viscido A, d’Angelo M, Panella G, Castelli V, Merola C, Frieri G, Latella G, Cimini A, Benedetti E. Inflammatory bowel disease: New insights into the interplay between environmental factors and PPARγ. Int J Mol Sci. 2021;22(3):985. https://doi.org/10.3390/ijms22030985 . PMID: 33498177; PMCID: PMC7863964.
doi: 10.3390/ijms22030985 pubmed: 33498177 pmcid: 7863964
Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9(6):367–74. PMID: 23935543; PMCID: PMC3736793.
pubmed: 23935543
Dubinsky M, Bleakman AP, Panaccione R, Hibi T, Schreiber S, Rubin D, Dignass A, Redondo I, Gibble TH, Kayhan C, Travis S. Bowel urgency in Ulcerative Colitis: current perspectives and future directions. Am J Gastroenterol. 2023;118(11):1940–53. https://doi.org/10.14309/ajg.0000000000002404 . Epub 2023 Jun 12. PMID: 37436151; PMCID: PMC10617668.
doi: 10.14309/ajg.0000000000002404 pubmed: 37436151 pmcid: 10617668
Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111 – 32. doi: 10.2147/CEG.S35942. PMID: 24872716; PMCID: PMC4026549.
Gordon M, Sinopoulou V, Ibrahim U, Abdulshafea M, Bracewell K, Akobeng AK. Patient education interventions for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;5(5):CD013854. https://doi.org/10.1002/14651858.CD013854.pub2 . PMID: 37172140; PMCID: PMC10162698.
doi: 10.1002/14651858.CD013854.pub2 pubmed: 37172140
Abbas N, Shakil M, Akhtar Rana Z, Basharat Ali S, Ayub Awan A, Gul S. A systematic review of the role of Diet in Ulcerative Colitis. Cureus. 2023;15(5):e39350. https://doi.org/10.7759/cureus.39350 . PMID: 37351247; PMCID: PMC10284595.
doi: 10.7759/cureus.39350 pubmed: 37351247 pmcid: 10284595
Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(4):235–41. PMID: 21857821; PMCID: PMC3127025.
pubmed: 21857821
Li C, Wu Y, Xie Y, Zhang Y, Jiang S, Wang J, Luo X, Chen Q. Oral manifestations serve as potential signs of ulcerative colitis: a review. Front Immunol. 2022;13:1013900. https://doi.org/10.3389/fimmu.2022.1013900 . PMID: 36248861; PMCID: PMC9559187.
doi: 10.3389/fimmu.2022.1013900 pubmed: 36248861 pmcid: 9559187
Valentini G, Ferrara SD’AgostinoE, Dolci M. 2023. Patients-reported oral manifestations in Coeliac Disease and Inflammatory Bowel diseases: an Italian survey oral 3, no. 3: 316–24. https://doi.org/10.3390/oral3030026
Tan CXW, Brand HS, Qaddour O, van der Bijl PML, De Boer NKH, Forouzanfar T, de Visscher JGAM. Knowledge and Interdisciplinary Communication of Gastroenterologists and dentists in the Netherlands about gastrointestinal diseases with oral manifestations. Crohns Colitis 360. 2022;4(1):otac006. https://doi.org/10.1093/crocol/otac006 . PMID: 36777554; PMCID: PMC9802256.
doi: 10.1093/crocol/otac006 pubmed: 36777554 pmcid: 9802256
Yin W, Ludvigsson JF, Liu Z, Roosaar A, Axéll T, Ye W. Inverse Association Between Poor Oral Health and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2017;15(4):525–531. https://doi.org/10.1016/j.cgh.2016.06.024 . Epub 2016 Jul 5. PMID: 27392757.
Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral manifestations of inflammatory bowel Disease and the role of non-invasive surrogate markers of Disease Activity. Med (Basel). 2020;7(6):33. https://doi.org/10.3390/medicines7060033 . PMID: 32560118; PMCID: PMC7345678.
doi: 10.3390/medicines7060033
Elahi M, Telkabadi M, Samadi V, Vakili H. Association of oral manifestations with ulcerative colitis. Gastroenterol Hepatol Bed Bench. 2012 Summer;5(3):155–60. PMID: 24834217; PMCID: PMC4017478.
Kumar KM, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: a pilot study. J Oral Maxillofac Pathol. 2018 May-Aug;22(2):199–203. https://doi.org/10.4103/jomfp.JOMFP_223_16 . PMID: 30158772; PMCID: PMC6097373.
Katz J, Shenkman A, Stavropoulos F, Melzer E. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis. 2003;9(1):34–40. https://doi.org/10.1034/j.1601-0825.2003.00879.x . PMID: 12617256.
Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013;19(46):8571–9. https://doi.org/10.3748/wjg.v19.i46.8571 . PMID: 24379574; PMCID: PMC3870502.
doi: 10.3748/wjg.v19.i46.8571 pubmed: 24379574 pmcid: 3870502
Mortada I, Leone A, Gerges Geagea A, Mortada R, Matar C, Rizzo M, Hajj Hussein I, Massaad-Massade L, Jurjus A. Oral manifestations of inflammatory bowel disease. J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):817–21. PMID: 28958141.
Harty S, Fleming P, Rowland M, Crushell E, McDermott M, Drumm B, Bourke B. A prospective study of the oral manifestations of Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(9):886 – 91. https://doi.org/10.1016/s1542-3565(05)00424-6 . PMID: 16234026.
Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Oral pathology in inflammatory bowel disease. World J Gastroenterol. 2016;22(25):5655–67. https://doi.org/10.3748/wjg.v22.i25.5655 . PMID: 27433081; PMCID: PMC4932203.
doi: 10.3748/wjg.v22.i25.5655 pubmed: 27433081 pmcid: 4932203

Auteurs

Nikta Taghizadeh Tabarsi (NT)

Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Nazanin Mortazavi (N)

Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran. mortazavi_nazanin@yahoo.com.
Department of Oral and Maxillofacial Medicine, School of Dentistry, Golestan University of Medical Sciences, PO Box 4916953363, Gorgan, Iran. mortazavi_nazanin@yahoo.com.

Alireza Norouzi (A)

Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

Sima Besharat (S)

Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

Nasser Behnampour (N)

Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Negar Asgari (N)

Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH